• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细菌脂肪酸生物合成:抗菌药物发现的基因组学驱动靶点。

Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery.

作者信息

Payne D J., Warren P V., Holmes D J., Ji Y, Lonsdale J T.

机构信息

Antimicrobials and Host Defence, 1250 South Collegeville Road, 19426, Collegeville, PA, USA

出版信息

Drug Discov Today. 2001 May 1;6(10):537-544. doi: 10.1016/s1359-6446(01)01774-3.

DOI:10.1016/s1359-6446(01)01774-3
PMID:11369293
Abstract

In this review we demonstrate how the interplay of genomics, bioinformatics and genomic technologies has enabled an in-depth analysis of the component enzymes of the bacterial fatty-acid biosynthesis pathway as a source of novel antibacterial targets. This evaluation has revealed that many of the enzymes are potentially selective, broad-spectrum antibacterial targets. We also illustrate the suitability of some of these targets for HTS. Furthermore, we discuss how the availability of a robust selectivity assay, mode-of-action assays and numerous crystal structures provide an excellent set of tools with which to initiate integrated programs of research to identify novel antibiotics targeted at these enzymes.

摘要

在本综述中,我们展示了基因组学、生物信息学和基因组技术之间的相互作用如何促成了对细菌脂肪酸生物合成途径中的组成酶进行深入分析,将其作为新型抗菌靶点的来源。这一评估表明,许多酶都有可能成为选择性、广谱抗菌靶点。我们还举例说明了其中一些靶点适用于高通量筛选。此外,我们讨论了强大的选择性测定法、作用机制测定法以及众多晶体结构的可用性如何提供了一套出色的工具,用以启动综合研究项目,以鉴定针对这些酶的新型抗生素。

相似文献

1
Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery.细菌脂肪酸生物合成:抗菌药物发现的基因组学驱动靶点。
Drug Discov Today. 2001 May 1;6(10):537-544. doi: 10.1016/s1359-6446(01)01774-3.
2
The impact of genomics on novel antibacterial targets.基因组学对新型抗菌靶点的影响。
Curr Opin Drug Discov Devel. 2000 Mar;3(2):177-90.
3
Novel targets for the future development of antibacterial agents.抗菌药物未来发展的新靶点。
Symp Ser Soc Appl Microbiol. 2002(31):28S-34S.
4
Novel targets for the future development of antibacterial agents.抗菌药物未来发展的新靶点。
J Appl Microbiol. 2002;92 Suppl:28S-34S.
5
Genomic approaches to antibacterial discovery.用于抗菌药物发现的基因组学方法。
Methods Mol Biol. 2004;266:231-59. doi: 10.1385/1-59259-763-7:231.
6
Novel antibacterials: a genomics approach to drug discovery.新型抗菌药物:药物发现的基因组学方法
Curr Drug Targets Infect Disord. 2002 Dec;2(4):291-308. doi: 10.2174/1568005023342227.
7
When will the genomics investment pay off for antibacterial discovery?基因组学投资何时能在抗菌药物发现方面取得回报?
Biochem Pharmacol. 2006 Mar 30;71(7):1096-102. doi: 10.1016/j.bcp.2005.11.025. Epub 2006 Jan 4.
8
Unraveling novel broad-spectrum antibacterial targets in food and waterborne pathogens using comparative genomics and protein interaction network analysis.利用比较基因组学和蛋白质相互作用网络分析揭示食品和水源性病原体中的新型广谱抗菌靶点。
Infect Genet Evol. 2014 Oct;27:300-8. doi: 10.1016/j.meegid.2014.08.007. Epub 2014 Aug 14.
9
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.社论:结核杆菌药物靶点的现状与展望以及基于构效关系的抗结核药物设计
Curr Pharm Des. 2014;20(27):4305-6. doi: 10.2174/1381612819666131118203915.
10
The targets of currently used antibacterial agents: lessons for drug discovery.当前使用的抗菌药物的作用靶点:药物研发的经验教训
Curr Pharm Des. 2007;13(30):3140-54. doi: 10.2174/138161207782110408.

引用本文的文献

1
Cloning, Expression, Purification and Biological Activity Analysis of Recombinant Helicobacter pylori FabI as a Drug Target.重组幽门螺杆菌FabI作为药物靶点的克隆、表达、纯化及生物学活性分析
Mol Biotechnol. 2025 Feb 27. doi: 10.1007/s12033-025-01411-x.
2
Evaluation of Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target.烯酰基辅酶 A 还原酶(FabK)作为一种窄谱药物靶点的评价。
ACS Infect Dis. 2024 May 10;10(5):1612-1623. doi: 10.1021/acsinfecdis.3c00710. Epub 2024 Apr 10.
3
Phytochemical Profiles and Biological Activities of Species: A Review.
物种的植物化学特征与生物活性:综述
Molecules. 2024 Feb 23;29(5):980. doi: 10.3390/molecules29050980.
4
Rethinking Biosynthesis of Aclacinomycin A.重新思考阿克拉霉素 A 的生物合成。
Molecules. 2023 Mar 18;28(6):2761. doi: 10.3390/molecules28062761.
5
The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development.结核分枝杆菌的致病机制:对新药研发的启示
Mol Biomed. 2022 Dec 22;3(1):48. doi: 10.1186/s43556-022-00106-y.
6
Transcriptome Analyses of Prophage in Mediating Persistent Methicillin-Resistant Endovascular Infection.介导耐甲氧西林的持续性血管内感染的噬菌体转录组分析。
Genes (Basel). 2022 Aug 25;13(9):1527. doi: 10.3390/genes13091527.
7
An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with Efficacy against Drug-Resistant Gram-Negative Infections.一种迭代方法指导发现法比霉素(FabI抑制剂),这是一种后期抗生素候选药物,对耐药革兰氏阴性菌感染有效。
ACS Cent Sci. 2022 Aug 24;8(8):1145-1158. doi: 10.1021/acscentsci.2c00598. Epub 2022 Aug 10.
8
Evaluation of microalgae and cyanobacteria as potential sources of antimicrobial compounds.评估微藻和蓝细菌作为抗菌化合物潜在来源的情况。
Saudi Pharm J. 2020 Dec;28(12):1834-1841. doi: 10.1016/j.jsps.2020.11.010. Epub 2020 Nov 26.
9
Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).mprF 基因突变与耐甲氧西林金黄色葡萄球菌 (MRSA) 对达托霉素和万古霉素的交叉耐药性有关。
Sci Rep. 2020 Sep 30;10(1):16107. doi: 10.1038/s41598-020-73108-x.
10
Ligand- and Structure-Based Approaches of Escherichia coli FabI Inhibition by Triclosan Derivatives: From Chemical Similarity to Protein Dynamics Influence.基于配体和结构的大肠杆菌 FabI 抑制剂三氯生衍生物:从化学相似性到蛋白质动力学影响。
ChemMedChem. 2019 Dec 4;14(23):1995-2004. doi: 10.1002/cmdc.201900415. Epub 2019 Nov 7.